Regeneron (REGN) Tops Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/8/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- Atlassian results seen as 'game changer' for AI kills software worries
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Regeneron (REGN) PT Raised to $659 at Brean Capital
August 4, 2015 3:47 PM EDTBrean Capital analyst Jonathan Aschoff reiterated a Buy rating and boosted his price target on Regeneron Pharma (NASDAQ: REGN) to $659.00 (from $525.00) following solid Q1 results, led by US Eylea sales of $655 million, which overwhelmingly beat consensus of $571 million.
Regeneron commented, ". Sales growth comprised a 21% QoQ increase in underlying physician demand, with distributor inventory levels remaining within the normal 1-2 week range. Importantly, Regeneron... More
Regeneron (REGN) PT Raised to $664 at Leerink Partners; Reacceleration in Eylea
August 4, 2015 3:45 PM EDTLeerink Partners analyst Joseph Schwartz reiterated an Outperform rating and bumped his price target on Regeneron Pharma (NASDAQ: REGN) to $664.00 (from $630.00) following solid Q2 results this morning. The analyst noted reacceleration in Eylea, particularly due to demand in diabetic macular edema (DME).
Schwartz... More
Regeneron Pharma's (REGN) Price Target Boosted to $665 at RBC
August 4, 2015 3:19 PM EDTRBC Capital maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $665.00 (from $570.00). Analyst Adnan Butt said the set up looks "ideal" for near and long-term outperformance.
"Eylea beat and guidance raise were substantial, driving nearterm gains. Mid-term... More
Regeneron Pharma's (REGN) Price Target Raised to $720 at Deutsche Bank
August 4, 2015 1:19 PM EDTDeutsche Bank maintained a Buy rating on Regeneron Pharma (NASDAQ: REGN) and raised its price target to $720.00 (from $650.00). The change follows Q2 results. Analyst Robyn Karnauskas noted Eylea is still growing at 50% year-over-year.
"Just when street was thinking about potential stabilization of Eylea share, 2Q US numbers surprised... More
